Pharsight

Alphagan P is owned by Allergan.

Alphagan P contains Brimonidine Tartrate.

Alphagan P has a total of 8 drug patents out of which 6 drug patents have expired.

Expired drug patents of Alphagan P are:

Alphagan P was authorised for market use on 16 March, 2001.

Alphagan P is available in solution/drops;ophthalmic dosage forms.

The generics of Alphagan P are possible to be released after 02 March, 2024.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295641 (Pediatric)	ALLERGAN	Compositions containing alpha-2-adrenergic agonist components	Jan, 2022 (1 year, 17 days ago)
US6562873 (Pediatric)	ALLERGAN	Compositions containing therapeutically active components having enhanced solubility	Jan, 2022 (1 year, 17 days ago)
US9687443 (Pediatric)	ALLERGAN	Compositions containing alpha-2-adrenergic agonist components	Jan, 2022 (1 year, 17 days ago)
US6627210 (Pediatric)	ALLERGAN	Compositions containing α-2-adrenergic agonist components	Jan, 2022 (1 year, 9 days ago)
US6673337 (Pediatric)	ALLERGAN	Compositions containing alpha-2-adrenergic agonist components	Jan, 2022 (1 year, 1 day ago)
US6641834 (Pediatric)	ALLERGAN	Compositions containing alpha-2-adrenergic agonist components	Jan, 2022 (11 months ago)
US8858961	ALLERGAN	Compositions containing alpha-2-adrenergic agonist components	Sep, 2023 (7 months from now)
US8858961 (Pediatric)	ALLERGAN	Compositions containing alpha-2-adrenergic agonist components	Mar, 2024 (1 year, 1 month from now)